Member Info for LordSnooty

http://www.nasdaq.com/markets/spos/

Mr Maguire has delegated me to tell all UK shareholders that they are at liberty to enter in the appropriate spaces on the NASDAQ application document, any figures that they consider suitable. being an aristocrat, I have entered an extremely large figure appropriate to my station in life.

the reverse split takes place at where we are now - $0.245. 20/1 takes the SP to $4.90, which is the OPKO deal's notional price. Then the IPO takes place at $4.90. Who knows, just thinking out loud.

I should add that the $0.49 share offer would of course be $9.80 after a 20/1 reverse split. But it remains to be seen what the actual figures are - mine is just an example for illustration.

Mr B - we need to get to at least $4 per share, it's one of the conditions of NASDAQ uplisting. To do that, there will be a reverse split - i.e. if you own 1000 shares at $0.25 now, with a 20/1 reverse split you will then own 50 shares at $5. The total value of your holding remains the same but the number of shares in issue is reduced. As yet it's not certain at what price the split will take place but the scenario I've outlined above looks plausible - i.e a 20/1 split at our current level. With 308m shares currently in issue, at $0.245 per share, our MCap is now around $75m. I expect that, once NASDAQ uplist is approved, the IPO will offer shares at a similar level to what the OPKO deal valued XBIO shares at notionally - $0.49. That's double where we are now. Once on NASDAQ it remains to be seen what news XBIO will offer to support the SP, and how the market values us in comparison with our peers. Parpaing discusses this issue a little in posts below. As a rough guide, if Virexxa and PSA-EPO news is good in coming months, perhaps we could see our MCap in the $250m-$350m range - but longer term, licensing and a royalty stream should mean much better than that. All this is of course subject to NASDAQ approval - and to XBIO's sclerotic habits.

Parps - feel free, because I don't know of any PIs that give a hoot about XBIO apart from us, and that's been one of the problems all along; all the legwork that Maguire supposedly put in to press the flesh with US investors over the last two years - what has it achieved but dilution by - guess who - not American investors but our Russian partners. And now, after three months' fantasy trading on OTC, so that we qualify for NASDAQ, we are back where we were a year ago - in the low twenties with almost no trades day-to-day. To say that I feel let down is something of an understatement, but what choice do we have but to sit tight and hope that Maguire pulls the proverbial rabbit from the hat.

http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11371446 p. 52: Item 2. Unregistered Sales of Equity Securities and Use of Proceeds On November 17, 2015, the Company and Relative Core Cyprus Limited, a limited liability company organized and existing under the laws of the Republic of Cyprus (“Relative Core”), entered into a stock exchange agreement (the “Exchange Agreement”) pursuant to which Relative Core agreed to transfer and sell to the Company that certain number shares of Xenetic Biosciences, Inc. (OTC:XBIO), a Nevada corporation (“Xenetic”), having a fair market value of $5 million in exchange for that number of shares of the Company’s common stock having a fair market value of $5 million. The transaction closed on January 5, 2016. The Company issued 494,462 shares of its common stock to Relative Core and received 10,204,082 shares of Xenetic common stock from Relative Core. The number of shares exchanged in the transaction was calculated based on the average closing sale price for the Company’s common stock on the NYSE for the ten (10) consecutive trading day period ending on the second day prior to the closing and the average closing sale price for Xenetic’s common stock on the OTC “Pink Sheet” for the ten (10) consecutive trading day period ending on the second day prior to the closing. The issuance of the 494,462 shares of common stock by the Company to Relative Core was made in reliance upon an exemption from the registration requirements under the Securities Act, pursuant to Regulation S and Section 4(2). So fair value for XBIO's shares was taken as $5m / 10,204,082 = $0.49 per share.

Draft prospectus out, fill in the blanks with whatever price you desire.

Hold on, NASDAQ may arrive soon.

Probably just the usual XBIO screw-up, Doze.

the Assett Purchase is consummated and Virexxa is ours. It also looks like ducks are being lined up for the reverse split: http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11349904

The problem , as all us long term and long-suffering sharholders know only too well, is that absolutely NOTHING ever happens when they say it will happen. Of course biopharma in general is notorious for its secrecy and its death marches to FDA approval, which take years, but XBIO takes the genre to another, glacial level. Every time any date is given, you can guarantee it will slip. Case in point: the Asset Purchase Agreement with Kevelt in November last year: this appears still not to have been consumated six months later, despite our escape from the OTC deathtrap being predicated on it. To say one is ****ed off is to put it mildly.

At least we appear to be stuck around 30c this time, not 18c like last year - until the money runs out again, no doubt.

Yeah, well, us long termers remember the cast iron promise of no later than Feb 2016, right?

he's gone for good...

Without any in-depth knowledge of the science, and going purely on the apparent synergies that you've dug up, I'd say there's a good chance that XBIO will be involved as the 'facilitator' of this OPKO candidate when it enters P 1 trials shortly. You could well be correct - this may be the long-awaited "novel application" talked of two years ago.

sorry to see you go and glad you got your money back. This hasn't exactly been a disaster for LTHs, but the best I can say personally is I'm doing better than the interest on the current account at Coutts. Still hoping against hope, probably foolishly given the track record, that Maguire's rabbit, in the form of an EPO licence-out, will miraculously appear sometime this year.

there will be a celebratory garden fete at Hacienda Snooty - details to be announced shortly. Chauffeurs will be particularly welcome.

I agree, this looks like someone has conflated and confused Baxalta's BAX 826, which uses XBIO's proprietory technology, with OPKO's Factor VIIa-CTP.

This news, though it's good that it is confirmed and on schedule, was anticipated in an XBIO release last October.